International Journal of Cardiology
Volume 135, Issue 3 , Pages 353-360 , 10 July 2009

Long-term cost-effectiveness of clopidogrel in STEMI patients

  • Zefeng Zhang

      Affiliations

    • School of Public Health, Nantong University, PR China
    • Emory University School of Medicine, Atlanta, GA, USA
    • Corresponding Author InformationCorresponding author. Emory Program in Cardiovascular Outcomes Research and Epidemiology, Emory University School of Medicine, 1256 Briarcliff Road, Suite 1N, Atlanta, GA 30306, USA. Tel.: +1 404 712 8422; fax: +1 404 727 6495.
    • ,
  • Paul Kolm

      Affiliations

    • Christiana Care Health System, Newark, DE, USA
    • ,
  • Frederique Mosse

      Affiliations

    • Sanofi-Aventis, Paris, France
    • ,
  • Joseph Jackson

      Affiliations

    • Bristol-Myers Squibb, Princeton, NJ, USA
    • ,
  • Liping Zhao

      Affiliations

    • Emory University School of Medicine, Atlanta, GA, USA
    • ,
  • William S. Weintraub

      Affiliations

    • Christiana Care Health System, Newark, DE, USA

Received 17 August 2007 ,Accepted 1 April 2008.

References 

  1. American Heart Association . Heart disease and stroke statistics — 2004 update. Dallas: American Heart Association; 2003;
  2. Steinhubl SR, Berger PB, Mann JT, et al. CREDO Investigators Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411–2420
  3. Yusuf S, Zhao F, Mehta SR, et al. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502
  4. Beinart SC, Kolm P, Veledar E, et al. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. J Am Coll Cardiol. 2005;46:761–769
  5. Weintraub WS, Mahoney EM, Lamy A, et al. CURE Study Investigators Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. J Am Coll Cardiol. 2005;45:838–845
  6. Mahoney EM, Mehta S, Yuan Y, et al. CURE Study Investigators Long-term cost effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. Am Heart J. 2006;151:219–227
  7. Sabatine MS, Cannon CP, Gibson CM, et al. CLARITY-TIMI 28 Investigators Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179–1189
  8. CCS-2 collaborative group. Rationale, design, and organisation of the second Chinese cardiac study (CCS-2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. J Cardiovasc Risk. 2000;7:435–441
  9. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1607–1621
  10. Yusuf S, Mehta SR, Zhao F, et al. Clopidogrel in Unstable angina to prevent Recurrent Events Trial Investigators Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation. 2003;107:966–972
  11. Mitchell J, Burge RT, Lee AJ, McCall NT. In: Per case prospective payment for episodes of hospital care. Springfield, VA: US Department of Commerce National Technical Information Service; 1995;
  12. Peeters A, Mamun AA, Willekens F, Bonneux L. A cardiovascular life history. A life course analysis of the original Framingham Heart Study cohort. Eur Heart J. 2002;23:458–466
  13. Brauer CA, Rosen AB, Greenberg D, Neumann PJ. Trends in the measurement of health utility in published cost-utility analyses.. Value Health. 2006;9:213–218
  14. Zeymer U, Gitt AK, Junger C, et al. Acute COronary Syndromes (ACOS) registry investigators Effect of clopidogrel on 1-year mortality in hospital survivors of acute ST segment elevation myocardial infarction in clinical practice. Eur Heart J. 2006;27:2661–2666
  15. Weintraub WS, Zhang Z, Mahoney EM, et al. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation. 2005;111:1106–1113
  16. Chan PS, Stein K, Chow T, Fendrick M, Bigger JT, Vijan S. Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population. J Am Coll Cardiol. 2006;48:112–121
  17. Eagle KA, Lim MJ, Dabbous OH, et al. GRACE Investigators A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA. 2004;291:2727–2733
  18. Savonitto S, Ardissino D, Granger CB, et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA. 1999;281:707–713
  19. Steg PG, Lopez-Sendon J, Lopez de Sa E, et al. GRACE Investigators External validity of clinical trials in acute myocardial infarction. Arch Intern Med. 2007;167:68–73

☆ This study was supported by a grant from sanofi-aventis and Bristol-Myers Squibb.

PII: S0167-5273(08)00559-7

doi: 10.1016/j.ijcard.2008.04.011

International Journal of Cardiology
Volume 135, Issue 3 , Pages 353-360 , 10 July 2009

Article Tools

* Image Usage & Resolution